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 Objectives: Real-time monitoring of disease status would be beneficial for timely 
decision making in the treatment of urothelial cancer (UC), and may accelerate the evaluation 
of clinical trials. Use of cell free tumour DNA (cftDNA) as a biomarker in liquid biopsy is 
minimally invasive and its successful use has been reported in various cancer types, including 
urothelial cancer. The objective of this study was to evaluate the use of digital droplet PCR 
(ddPCR)-based assays to monitor urothelial cancer after treatment.  
 Method and Materials: Blood, urine and matching formalin fixed, paraffin 
embedded (FFPE) diagnostic specimens were collected from 20 patients diagnosed with stage 
T1 (n=2) and T2/T3 (n=18) disease. SNaPshot assays, Sanger sequencing and whole exome 
sequencing (WES) were used to identify tumour-specific mutations and somatic mutation 
status was confirmed using patient-matched DNAs extracted from buffy coats and peripheral 
blood mononucleocytes. The ddPCR assays of the tumour-specific mutations were used to 
detect the fractional abundance of cftDNA in plasma and urine. 
 Results: SNaPshot and Sanger sequencing identified point mutations in 70% of the 
patients that were assayable by ddPCR. Cases of remission and relapse monitored by assays 
for PIK3CA E542K and TP53 Y163C mutations in plasma and urine concurred with clinical 
observations up to 67 months from the start of neoadjuvant chemotherapy. A new ddPCR 
assay for the TERT promoter (-124) mutation was developed. The TERT assay was able to 
detect mutations in cases below the limit of detection by SNaPshot. WES identified a novel 
mutation, CNTNAP4 G727*. A ddPCR assay designed to detect this mutation was able to 
distinguish mutant from wild type alleles.  
 Conclusions: The study demonstrated that ddPCR assays could be used to detect 
cftDNA in liquid biopsy monitoring of the post-therapy disease status in patients with 
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urothelial cancer. Overall, 70% of the patients in our study harboured mutations that were 
assayable by ddPCR. 
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Urothelial carcinoma (UC) is the 10th most common cancer, with 550,000 new cancer 
cases worldwide in 2018 [1]. Risk of progression from non-muscle-invasive bladder cancer 
(NMIBC) to MIBC is high in T1 disease, up to 17% at one year, increasing to 45% at 5 years 
[2]. High-risk NMIBC and MIBC are treated aggressively, often by cystectomy with peri-
operative chemotherapy in the case of MIBC. Effectiveness of treatments of metastatic 
disease is limited [3, 4]. The recent technological advance in identifying cell free tumour 
DNA (cftDNA) offers the opportunity to enable real-time diagnosis in combination with new 
and existing diagnostic modalities, which may facilitate the selection of therapy options and 
more accurate prediction of disease prognosis [5].    
 DNA is released into the bloodstream or urine as cell-free DNA (cfDNA), and DNA 
released from tumours, cftDNA, can be differentiated from normal cfDNA using tumour-
specific mutations as markers [6]. Use of cftDNA-based markers in liquid biopsy samples 
may enable a minimally invasive approach to disease monitoring, and facilitates longitudinal, 
repeated sampling. cftDNA is detectable in many cancer types, including UC [7], albeit the 
levels may vary [8]. Studies showed that real-time monitoring of tumour burden is possible, 
when measured as variant allele frequency or fractional abundance (FA) of cftDNA, and it 
can represent DNA from both primary and metastatic tumours [6, 9, 10].  
 Detection of the UC hotspot mutations FGFR3 S249C and Y373C, and PIK3CA 
E545K in plasma and urine cfDNA was used in disease surveillance, and this showed that the 
level of cftDNA was associated with later disease progression in NMIBC and recurrence in 
patients that were undergoing cystectomy [11]. A custom-designed panel of one to six 
patient-specific ddPCR assays, developed based on the pre-screening of the tumour-specific 
mutations by next-generation sequencing, were successfully utilised in longitudinal 
monitoring of NMIBC [12]. An extension of this strategy that used 84 personalized ddPCR 
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assays targeting 61 genes in cftDNA detected a relapse in MIBC patients with a lead-time of 
101 days after cystectomy over radiographic imaging [13]. The level of cftDNA in liquid 
biopsy could be detected by a panel of general or UC-specific mutations and structural 
alterations, such as copy number alterations (CNAs) [13-18].  
 The underlying principle of ddPCR is a single PCR reaction split into 10,000 to 
20,000 discreet measurements in "droplets", which enables quantification of a single mutant 
DNA sequence amongst thousands of wild type sequences [6]. While relatively limited in the 
flexibility of mutational coverage in monitoring patients, it does have an advantage in 
simplicity and sensitivity. In this study, we have tested the feasibility and practicality in 
performing commercially available ddPCR-based assays and in designing new ddPCR assays 
where pre-existing assays were not available.  
 
2. Materials and Methods 
 
2.1. Patients and DNA samples 
 Samples were collected under the approvals by The West of Scotland Research Ethics 
Service (REC 10/S0704/18) and MI84 ECMC Blood Biomarkers Study. The survival status 
of patients is as of 1/1/2018. The matched Formalin Fixed Paraffin Embedded (FFPE) 
samples were acquired from the NHS Greater Glasgow and Clyde Biorepository 
(16/WS/0207 app 122). Blood samples were processed at the Queen Elizabeth University 
Hospital or The Analytical Services Unit (ASU), University of Glasgow. Macrodissection of 
tumour areas, identified by the pathologist, was performed from five to ten 8-µm FFPE tissue 
sections. DNAs from plasma, buffy coat and peripheral blood mononucleocytes (PBMCs) 




2.2. SNaPshot assay and Sanger sequencing 
 Hotspot mutations in the TERT promotor, PIK3CA, FGFR3 and RAS genes were 
assayed by SNaPshot analysis [19] in tumour DNAs. Sanger sequencing was used to identify 
TP53 mutations. The patient-matched buffy coat DNAs were used as control for somatic 
mutations. Further details of SNaPshot assay and Sanger sequencing are provided in 
Supplementary Methods.  
 
2.3. Whole Exome Sequencing (WES) 
 WES and the subsequent bioinformatic analysis was performed by Glasgow Polyomics 
Facility, University of Glasgow. Whole exome capture was carried out using the SeqCap EZ 
Exome+UTR kit (Roche, Pleasanton, CA, USA), sequenced using the NextSeq 500 platform 
(Illumina, San Diego, CA, USA) and 2x 75 bp reads were generated. The sequence data was 
aligned to the GRCh37 (hg19) genome using BWA (Version 0.7.10-r789) and variants were 
called using the Genome Analysis Toolkit (GATK, Broad Institute, Cambridge, USA). 
Tumour-specific mutations were identified by removing germ-line variants identified in 
PBMCs. Variant annotation and effect prediction was completed using SnpEff [20]. 
 
2.4. The ddPCR 
 A typical ddPCR experiment consisted of a control amplification without the addition 
of template DNA, negative (tumour DNA that does not carry the mutation) and positive 
(tumour DNA that carries the mutation) controls, along with the assays performed with plasma 
and urine cfDNA. BioRad C1000 Touch thermos cycler was used for PCR in droplets 
generated, which were analysed by the QX200 droplet digital PCR system and Quantasoft 
(BioRad, Watford, UK). FA of the mutant allele was calculated as the number of droplets 
positive with mutant amplicon, divided by total droplets positive with amplicons. The assays 
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were repeated in at least three independent experiments. The CNTNAP4 assay was carried out 





3.1. Patient characteristics 
 A cohort of 20 patients (2 NMIBC and 18 MIBC) was available (Table 1). Eight 
patients had recurrent disease, 5 of whom had a single recurrence, while others had 3 or 
more. Of 11 deceased patients, 8 (73%) had metastasis. Metastasis was identified in 11% (1 
out of 9) of patients who are alive. Cystectomy with neoadjuvant chemotherapy, radiotherapy 
with or without chemotherapy were the most common treatment types (70% combined) 






















































 All patients (n = 20) 
 Number % 
Sex   
  Male 17 85.0 
  Female 3 15.0 
Age (Years)   
  Range 43-83  
  Median 67  
  Mean 68  
T Stage   
  pT1 2 10.0 
  pT2 18 90.0 
Grade   
  2 1 5.0 
  3 19 95.0 
Recurrence/Outcome   
  Clinical Recurrence 8 40.0 
  No Recurrence 12 60.0 
Current Status   
  Alive 9 45.0 
  Deceased 11 55.0 
Presence of Metastasis   
  No metastasis  11 55.0 
  Metastasis present 9 45.0 
Survival Time, mean (months)   
  No metastasis 53.8  
  Metastasis present 31.5  
Treatments   
  Cystectomy only 2 10.0 
  Cystectomy and Neo. Adj. Chemotherapy 5 25.0 
  Cystectomy and Radiotherapy 1 5.0 
  Radiotherapy only 6 30.0 
  Radiotherapy and Chemotherapy 3 15.0 
  Chemotherapy only 2 10.0 
  Nephroureterectomy 1 5.0 
Presence of mutations identified in each patient   
  Two mutations 3 15.0 
  Single mutation 11 55.0 
  No mutation  6 30.0 
Mutations identified by SNaPshot    
  PIK3CA E542K 1 5.0 
  PIK3CA E545K 2 10.0 
  TERT -124 11 55.0 
  FGFR3 K650/652M 1 5.0 
Mutations identified by Sanger sequencing   
  TP53 Y163C  1 5.0 
  TP53 P278T 1 5.0 
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Table 2. Details of patients and tumour samples  
 
 






Sex Age Tumour 
Stage/ 
Grade 
Recurrence Metastasis Survival* 
(Months) 
Treatment 1 Treatment 2 Mutations identified in tumour by 
SNaPshot/Sanger sequencing  
1 M 57 pT1bG2 1 0 62 (Alive)  Neoadjuvant 
Chemotherapy 
Cystectomy  TERT -124, FGFR3 K650/652M 
2 M 62 pT1cG3 1 0 56 (Alive)  Nephroureterectomy   
3 M 77 pT2G3 0 0 60 (Alive)  Neoadjuvant 
Chemotherapy 
Cystectomy  TERT -124, PIK3CA E542K 
4 M 67 pT2G3 0 0 49 (Alive) Radiotherapy Chemotherapy TERT -124 
5 M 81 pT2G3 0 0 50 (Alive)  Neoadjuvant 
Chemotherapy 
Cystectomy  TERT -124  
6 M 67 pT2G3 0 0 57 (Alive)  Radiotherapy Chemotherapy  
7 F 83 pT2G3 0 0 70 (Alive)  Radiotherapy  TERT -124 
8 M 65 pT2G3 0 0 64 (Alive)  Radiotherapy  TP53 P278T 
9 M 66 pT2G3 0 0 47  Chemotherapy  TP53 Y163C 
10 M 64 pT2G3 1 0 46  Radiotherapy  TERT -124 
11 M 68 pT2G3 3 1 57 (Alive)  Cystectomy Radiotherapy TERT -124 
12 M 79 pT2G3 3 0 27 Radiotherapy   
13 M 63 pT2G3 0 1 29 Radiotherapy  PIK3CA E545K 
14 M 69 pT2G3 0 1 18 Neoadjuvant 
Chemotherapy 
Cystectomy  TERT -124 
15 M 70 pT2G3 0 1 28 Cystectomy  TERT -124 
16 M 61 pT2G3 0 1 32 Chemotherapy   
17 F 43 pT2G3 1 1 11 Neoadjuvant 
Chemotherapy 
Cystectomy  TERT -124, PIK3CA E545K 
18 M 77 pT2G3 1 1 28 Radiotherapy Chemotherapy TERT -124 
19 F 82 pT2aG3 0 1 21 Cystectomy   




3.2. SNaPshot and Sanger sequencing identified assayable mutations in 70% of samples 
 PIK3CA E542K, PI3KCA E545K and telomerase reverse transcriptase (TERT) 
promoter (-124) mutations were identified by SNaPshot assays in 5%, 10% and 55% of 
patients, respectively (Table 1, Table 2). TP53 mutations (P278T and Y163C) were identified 
by Sanger sequencing in 10% of the patients. No FGFR3 S249C or RAS gene mutations were 
detected. Overall, no mutations were identified in 30% of the cases. 
 
3.3. ddPCR analysis of a PIK3CA E542K mutation in plasma cftDNA from a case in 
remission 
Patient 3 was a 77-year-old male with a pT2 G3 tumour that carried a PIK3CA E542K 
mutation as identified by SNaPshot (Table 2). The presence of the PIK3CA E542K mutation 
was confirmed in the patient’s tumour DNA by ddPCR using a commercially available, 
validated assay (Fig. 1C, Supplementary Results). No mutant signals were observed in 
negative controls, in the absence of template DNA, or in the tumour DNA from Patient 14, 
that was wildtype for the PIK3CA E542K mutation by SNaPshot (Fig. 1A, B).  The mutant 
allele was detected in the plasma of Patient 3 at 1 week after the start of neoadjuvant 
chemotherapy (Fig. 1D), however, it was not detected at 46 months post-cystectomy (Fig. 
1E). A minimum of 3 independent experiments were performed and the results were 
replicated (Fig. 1F). The patient is currently in remission after 5 years and believed to be 
disease free. Therefore, ddPCR-based monitoring of the PIK3CA E542K mutation concur 




Fig. 1: ddPCR-based detection of a PIK3CA E542K mutation in plasma ctDNA from a 
case of remission. The plots (A-E) indicate the digital PCR droplets positive with wild type 
(green), mutant (blue), both mutant and wild type (red) amplicons, and those with no 
amplicons (black). The assays were performed along with negative controls in which no 
template DNA was added (A) and tumour DNA known to be negative for this mutation 
(Patient 14) (B). The PIK3CA E542K assays were performed to monitor the disease status of 
Patient 3, using DNAs extracted from tumour (C), plasma collected at 1 week after the start 
of neoadjuvant chemotherapy, before cystectomy (D), and plasma collected at 46 months 
after cystectomy (E). (F) Summary of fractional abundance of the mutant allele within total 





Figure 1: PIK3CA E542K
No Template Control
1 week after the start of 
chemotherapy, before cystectomy 46 months post-cystectomy
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3.4. ddPCR analysis of a TP53 Y163C mutation in plasma and urine ctDNA from a relapsed 
case 
Patient 9 was a 66-year-old male with a pT2 G3 tumour that was identified with a 
TP53 Y163C mutation by Sanger sequencing (Table 2). The TP53 Y163C mutation was 
confirmed in the patient’s tumour DNA by a commercially available, validated ddPCR assay 
(Fig. 2A). No mutant alleles were detected by ddPCR in plasma collected at 31 weeks into 
chemotherapy (Fig. 2B). However, mutant alleles were detected in plasma, as well as in 
urine, collected at 67 months after the initiation of chemotherapy (Fig. 2C-E). Clinically, the 
patient relapsed and has since died from UC.  
 
Fig. 2: ddPCR-based detection of a TP53 Y163C mutation in plasma and urine cell-free 
tumour DNA from a case of relapse. The TP53 Y163C ddPCR assays were performed to 
monitor the disease status of Patient 9, using DNAs extracted from tumour (A), plasma 
collected at 8 months (B), and plasma (C) and urine (D) collected at 67 months after the 
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3.5. Application of the new TERT -124 ddPCR assay to the monitoring of plasma from cases 
of patients in remission 
The TERT -124 mutation was identified in 55% of our patients (n=11/20) by SNaPshot 
assay (Table 1). In order to take advantage of this common mutation, a ddPCR assay was 
designed with a new set of probes and previously reported PCR amplification primers [21, 22] 
(Supplementary Results, Fig S1, Fig S2). The new assay was able to detect the presence of the 
TERT -124 mutation correctly with the level of detection (LOD) of 0.5% (Fig S1). The LOD 
of SNaPshot is reported to be between 5-10% [19]. Our results showed that the new ddPCR 
assay could detect the mutant allele in cases below the detection limit of SNaPshot (Fig S2).   
A TERT -124 mutation had been identified in the tumour of Patient 3 by SNaPshot 
(Table 2), as well as the PIK3CA E542K mutation (Fig. 1). The new ddPCR assay showed 
mutant droplets in the patient’s tumour DNA (Fig. 3A) with the FA of 74.1% (Fig. 3D). 
TERT -124 mutant alleles were detected in the plasma collected at 1 week from the start of 
neoadjuvant chemotherapy (Fig. 3B) with a FA of 36.0% (Fig. 3D). In contrast, the mutant 
droplets were not detected in the plasma at 46-months post-cystectomy (Fig. 3C, D). These 
results are in accordance with our observations for the PIK3CA E542K mutation in Patient 3 
(Fig. 1). 
 Furthermore, a TERT -124 mutation was identified in Patient 11, a 68-year-old male 
with a pT2 G3 tumour, by SNaPshot (Table 2). Patient’s tumour DNA was shown to be 
positive for the mutant alleles by ddPCR (Fig. 3E) with a FA of 42.1% (Fig. 3I). Although 
some mutant droplets were observed in the plasma collected at 1 month after the start of 
chemotherapy prior to cystectomy (Fig. 3F), the FA value (7.0% ± 7.0%) was below the LOD 
for the assay (Fig. 3I). The number of mutant signals detected by ddPCR increased in the 
plasma collected at 2 months and 17 months post-cystectomy (Fig. 3G, H), with a FA of 
16.0% and 24.4%, respectively (Fig. 3I). Clinically, the patient remains in remission (Table 2). 
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As the patient also had a previous relapse with metastasis, his disease status is being carefully 
monitored by the oncologist.  
 
Fig 3: ddPCR-based detection of the TERT -124 mutation in plasma ctDNA from cases 
of remission and relapse. The new TERT -124 ddPCR assays were applied to monitor the 
disease status of Patient 3 (A-D) and Patient 11 (E-I). The plots show the results of the assay 
performed using DNAs extracted from tumour (A, E), plasma at 1 week after the initiation of 
neoadjuvant chemotherapy, before cystectomy (B), 46 months post-cystectomy (C), 1 month 
after the initiation of neoadjuvant chemotherapy, before cystectomy (F), 2 months post-
cystectomy (G), and at 17 months post-cystectomy (H). Fractional abundance of the mutant 
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3.6. The ddPCR assay for CNTNAP4 gene developed from WES presented a case of relapse 
 To identify patient-specific tumour mutations in an unbiased fashion, WES was 
performed in DNAs extracted from FFPE tumours (n=3, Patient 4, 5, and 6) (Fig. 4, 
Supplementary Results, Fig S3A). Three adjacent areas within one FFPE block from Patient 5 
were also sampled to assess the variability of mutations. We found that adjacent areas 5-1, 5-2 
and 5-3, contained 19883, 19858 and 21785 tumour-specific mutations, respectively. This was 
close to the reported mutation rate [23]. Among these, 142 mutations were identified as 
common (Fig. 4A). Following a systematic filtering, we selected a Contactin-Associated 
Protein-Like 4 (CNTNAP4) G727* mutation for assay development. We confirmed the 
presence of this mutation in the tumour DNA by Sanger sequencing, as a secondary peak 
showing a C>A mutation (Fig. 4B). A new ddPCR assay designed was able to distinguish 
mutant and normal genomic DNAs with the LOD of 1% FA of mutant allele (Supplementary 
Results, Fig S4). 
 Patient 5 was an 81-year-old male with a pT2 G3 tumour that carried a TERT -124 
mutation (Table 2, Fig S2A, S3) in addition to the CNTNAP4 G727*. The presence of the 
CNTNAP4 G727* mutation was confirmed in the patient’s tumour DNA by ddPCR (Fig. 4C) 
with a FA of 7.31% (Fig. 4G). Mutant droplets were observed in plasma collected 2 months 
into neoadjuvant chemotherapy and at 38 months post-cystectomy, with the FA of 0.25% and 
0.4%, respectively (Fig. 4D,E,G). However, in the urine collected at 38 months post-
cystectomy, the mutant droplets were detected at FA of 4.8%, i.e. above the LOD (Fig. 4F). 
The result from urine suggested that this patient may be relapsing, although there was no 




Fig. 4: ddPCR-based detection of a CNTNAP4 G727* mutation identified by WES in 
the plasma and urine from a case of relapse. (A) Number of tumour-specific mutations 
identified by WES in three adjacent areas (5-1, 5-2, 5-3) of tumours in Patient 5. 142 
mutations were found in common between 5-1, 5-2 and 5-3. (B) Sanger sequencing 
confirmed the presence of the CNTNAP4 G727* mutation in tumour area 5-1 (arrow). The 
plots show the results of the new CNTNAP4 G727* ddPCR assay performed on DNAs 
extracted from tumour (C), plasma collected at 2 months after the start of neoadjuvant 
chemotherapy before cystectomy (D), and plasma (E) and urine (F) collected at 38 months 
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4. Discussion  
 While a good range of ddPCR assays are commercially available for the detection of 
hotspot mutations in PIK3CA and FGFR3, a limited range was available for TP53 mutations, 
likely due to these mutations being distributed across the gene [24, 25]. Some commercial 
ddPCR assays are validated in silico, however, this did not guarantee that the assays would 
work. We were not able to design a functional FGFR3 K650/652M ddPCR assay due to 
persistent false-positive signals.  
 Inhibition of PI3K was shown to suppress bladder tumours particularly effectively in 
the presence of PIK3CA hotspot mutations, as evaluated in human urothelial cell lines and in 
xenograft mouse models [26]. Various inhibitors for PI3K/AKT/mTOR signalling pathways 
are currently in clinical trials for advanced solid tumours, including those of the bladder [27, 
28], and evaluation of PIK3CA mutational status as a biomarker is a rational approach in 
patient selection, at least in the trial set up.   
 TERT is a part of telomerase protein complex that plays a role in extending the 
telomere length [29]. TERT promotor at -124 and -146 are mutated frequently in UC across 
all stages, but not in normal bladder tissues [29-31]. These mutations are predicted to increase 
the level of TERT transcripts, leading to pro-tumour telomerase activity [29]. Several studies 
have investigated the usefulness of TERT promotor mutations as a urinary cell free 
biomarker, using SNaPshot [21, 22], ddPCR [30] and next generation sequencing with urine 
sediment DNA [32]. Telomerase inhibitors are in clinical trials based on the likely 
involvement of telomerase activity in tumour progression [29]. The ddPCR assay in this 
study produced meaningful results with as little as 1 ng of DNA as starting material, in 
contrast to SNaPshot that required 5 ng [33]. 
 CNTNAP4 (CASPR4) is a member of Neurexin-IV/Caspr/Paranodin (NCP) family of 
cell adhesion and recognition molecules and is expressed in neuronal subpopulations in 
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specific brain regions [34]. A function as a tumour suppressor was shown in the other family 
member CNTNAP2 (CASPR2) [35]. According to TCGA database (portal.gdc.cancer.gov) 
[36], 28 different CNTNAP4 mutations were identified in 6.80% (28/412) of UC. CNTNAP4 
mutations were also identified at a high frequency in lung, colorectal cancer, and melanoma 
(68-82%), and at a lower frequency in breast cancer (15%). Mutation at the G727 site, G727V 
has been identified in colorectal cancer [37], however, G727* mutation has not been reported 
so far.  
 Stratification strategies for neoadjuvant therapy and surveillance in conjunction with 
cftDNA analysis have been proposed [14, 16]. Use of cftDNA monitoring in the course of 
checkpoint immunotherapy is also possible [38, 39]. A novel concept of an integrated 
monitoring system, such as continuous individualised risk index (CIRI) is based on the 
advance of cftDNA-based technologies [5]. The cost effectiveness of ddPCR should be 
carefully evaluated, as repeat cystoscopies are expensive for health services [40] and tests for 
several mutations in genes such as FGFR3, PI3KCA, and TP53 are already available as 
molecular diagnostic services offered by the National Health Service in the UK. Given that the 
cfDNA technology has still not been implemented widely in the health service, clinical 
applicability of ddPCR-based approaches may lie in the feasibility of use of such assays in a 
clinical setting. 
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Highlights: 
 Digital Droplet PCR assays of tumour-specific mutations can be used to monitor cell 
free tumour DNA levels in plasma and urine in bladder cancer patients. 
 Seventy percent of the patients in our study harboured mutations that were assayable 
by ddPCR. 
 Commercially available ddPCR assays for PIK3CA E542K and TP53 Y163C can be 
used to assess disease status.  
 A new ddPCR assay for TERT promotor (-124) enables detection at a lower fractional 
abundance than SNaPshot.  
 A ddPCR assay was developed to detect a novel mutation, CNTNAP4 G727*, 
identified by whole exome sequencing. 
 
Highlights (for review)
